MindMed Archives

Psychedelics News

MindMed

Finance

6 Oct 2022

Can Psychedelic Stocks Like MindMed and atai Ever Recover?

Should investors begin ringing the funeral bells for psychedelic stocks? Can psychedelic stocks Like MindMed and atai ever recover? James Hallifax takes a deeper look....

By James Hallifax

Industry

29 Sep 2022

MindMed in Trouble? Serious Problems or Retail Panic?

MindMed stock has been dropping and investors are concerned....

By Jason Najum

Don’t Miss

26 Sep 2022

News You Might Have Missed: Sep 26th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Industry

20 Sep 2022

MindMed Doses First Patients in Phase 1 MDMA Trial

MindMed Collaborators Dose First Subject in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

8 Sep 2022

MindMed Faces Tough IP Questions (and Publishes Positive Trial Results)

MindMed’s been in the news as of late....

By Jason Najum

Don’t Miss

29 Aug 2022

News You Might Have Missed: Aug 29th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Finance

27 Aug 2022

MindMed Completes 1-for-15 Reverse Share Split

MindMed Completes 1-for-15 Reverse Share Split....

By Microdose NewsDesk

Industry

25 Aug 2022

MindMed Doses First Patient in Phase 2b Trial

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder...

By Microdose NewsDesk

Industry

18 Aug 2022

MindMed’s Path Through the Clinical Trial Process

On January 25th, 2022 the Food and Drug Administration (FDA) cleared MindMed’s MM-120 Investigational New Drug (IND), an LSD-based drug directed at treating generalized anxiety disorder, the first of its...

By Robert Toland

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result